LifeSciences BC > News > Member Announcements

LifeSciences BC Announces Appointment of Richard Osborn to Board of Directors

November 20, 2017
LifeSciences BC

Richard Osborn Vancouver, B.C. – November 16, 2017, Dr. Lesley Esford, President & CEO of LifeSciences BC, is pleased to announce that Richard Osborn has joined the LifeSciences BC Board of Directors.  Richard is the Managing Partner of TELUS Ventures, the strategic investment arm of TELUS Corporation. Before joining TELUS Ventures in 2016, Richard was … Continue reading LifeSciences BC Announces Appointment of Richard Osborn to Board of Directors

CDRD Appoints Dr. Rachael Ritchie Vice President, Strategy and Partnerships

November 16, 2017
The Centre for Drug Research and Development

Vancouver, Canada – November 16, 2017: The Centre for Drug Research and Development (CDRD), Canada’s national drug development and commercialization engine, is pleased to announce the appointment of Dr. Rachael Ritchie as Vice President, Strategy & Partnerships effective December 1, 2017. Dr. Ritchie brings to CDRD a background that spans the University of British Columbia, … Continue reading CDRD Appoints Dr. Rachael Ritchie Vice President, Strategy and Partnerships

Aequus Granted European Patent for Once-Weekly Transdermal Aripiprazole

November 16, 2017
Aequus Pharmaceuticals Inc.

VANCOUVER, BC. November 16th, 2017 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that the European Patent Office has issued an intention to grant a European patent for AQS1301, Aequus’ once-weekly transdermal patch containing aripiprazole. … Continue reading Aequus Granted European Patent for Once-Weekly Transdermal Aripiprazole

Arbutus’ LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran

November 16, 2017
Arbutus Biopharma Corporation

VANCOUVER, B.C. and WARMINSTER, Pa., Nov. 16, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the Company’s lipid nanoparticle (LNP) licensee Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), initiated submission of a rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for … Continue reading Arbutus’ LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran

DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2018 Financial Results

November 14, 2017
DelMar Pharmaceuticals Inc.

Company will host a business update conference call and webcast on Tuesday, November 14, 2017 at 4:30 PM EST – VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 13, 2017 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for … Continue reading DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2018 Financial Results

Arbutus’ LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA)

November 14, 2017
Arbutus Biopharma Corporation

VANCOUVER, British Columbia and WARMINSTER, Pa., Nov. 13, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the Company’s lipid nanoparticle (LNP) licensee Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), announced the grant of an accelerated assessment from the European Medicines Agency (EMA) for patisiran, an investigational … Continue reading Arbutus’ LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA)

Zymeworks Announces License Agreement with Johnson & Johnson Innovation to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics

November 14, 2017
Zymeworks Inc.

Zymeworks licenses the Azymetric™ and EFECT™ platforms to Janssen US$50 million upfront license fee paid to Zymeworks for up to six bispecific programs VANCOUVER, British Columbia–(BUSINESS WIRE)– Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, today announced it has executed a licensing agreement with Janssen … Continue reading Zymeworks Announces License Agreement with Johnson & Johnson Innovation to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics

bioLytical Laboratories named BC Export Award Finalist

November 9, 2017
bioLytical Laboratories

RICHMOND, BC, Nov. 9, 2017 /CNW/ – bioLytical Laboratories has been announced as a finalist of Business in Vancouver’s 2017 BC Export Awards in the Emerging Exporter category. bioLytical is the developer and manufacturer of INSTI, an HIV test that provides results in 1 minute.  Headquartered in Richmond, bioLytical employs 60 people in BC in addition to a sales force in … Continue reading bioLytical Laboratories named BC Export Award Finalist

More Than Engaging with Government – Let’s Work Together

November 9, 2017
Novateur Ventures

by Ali Ardakani | Nov 7, 2017 | Biotechnology, British Columbia, Government, Life Sciences | On November 2, 2017, I had the pleasure and opportunity to represent LifeSciences BC board, together with Nancy Harrison, Chair, Board of Directors, Dr. Lesley Esford, President & CEO, along with other board members, Dr. Pieter Cullis and Scott Phillips. Our visit included breakfast with the NDP … Continue reading More Than Engaging with Government – Let’s Work Together

Qu Biologics recruits Ms. Jennifer Archibald, Chief Financial Officer, and Mr. Alun Rees, VP, Manufacturing, to Leadership Team

November 8, 2017
Qu Biologics Inc.

Vancouver, British Columbia – November 8th, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to “reboot” the body’s innate immune system, has brought on board two highly experienced biotech executives, to round out the leadership team of the company. Ms. Jennifer Archibald has joined … Continue reading Qu Biologics recruits Ms. Jennifer Archibald, Chief Financial Officer, and Mr. Alun Rees, VP, Manufacturing, to Leadership Team